No Data
Cybin Inc. Advances in Mental Health Treatments
Express News | Cybin Inc - Cyb003 Demonstrates Excellent Safety Profile
Express News | Cybin Inc - 100% Response, 71% Remission at 12 Months With Cyb003
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
Press Release: Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
No Data